ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Complete echo reports with zero clicks. Us2.ai is using augmented intelligence to Ultrasound Anybody Anywhere.
The term “open abdomen” refers to a surgically created defect in the abdominal wall that exposes abdominal viscera. Leaving an abdominal cavity temporarily open has…
As every year, the AcuteCVdays Campaign will run from April 29th until June 2nd. The 2024 edition will focus on “An update on device-therapy in…
Abstract. In 2023, cardiovascular imaging has made significant advancements, in terms of technology, pathophysiology and clinical application. In this revi
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Nitin Jain, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, of Oncology Brothers to discuss treatment sequencing for chronic lymphocytic leukemia, covering both first-line…
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are both major global public health burdens, with a burden of 74·4 million and 393 million disability-adjusted…
Advances in Therapy – Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden and is the third leading cause of death worldwide. A…
Ischemic heart disease (IHD) is the leading cause of morbidity and mortality in both genders; however, young women fare the worst, likely reflecting the more…
AbstractBackgroundThe expansion of hematopoietic stem cells caused by acquired somatic mutations (clonal hematopoiesis [CH]) is a novel cardiovascular risk factor. The prognostic value of CH…